The firm said it will use the net proceeds for R&D, including the continued development of its Acuitas AMR gene panels.
The firm plans to use the $13.3 million in net proceeds to fund ongoing operations, expansions of its liquid biopsy business, and to service its indebtedness.
The company plans to use proceeds to support its ongoing operations, expansion of its business, and to service existing debts.
The company said it anticipates using net proceeds for working capital and general corporate purposes.
The firm is offering 12.1 million shares of its common stock at a price to the public of $2.90 per share, for expected gross proceeds of $35.1 million.
The company said after the close of the market Tuesday that it intends to offer 10 million shares of its common stock in an underwritten public offering.
Net proceeds from the offering of more than 4.9 million shares will be used for working capital and other general corporate purposes.
The offering was a follow-on to a capital raise during the summer that brought in $6 million. The company's CEO said the additional financing was needed to execute on its business plan.
The firm raised €4.7 million through a conditional placement, and €5.0 million through an unconditional direct subscription.
Earlier this month, Angle placed about 34.8 million new ordinary shares at 35 pence per share, grossing £12.2 million.
The Wall Street Journal looks into FamilyTreeDNA's handling of genetic genealogy searches by law enforcement.
In a point-counterpoint in the Boston Globe, researchers discuss the potential of gene editing to prevent Lyme disease, but also the pitfalls of doing so.
MIT's Technology Review reports that researchers hope to develop a CRISPR-based pain therapy.
In Science this week: atlas of malaria parasites' gene expression across their life cycles, and more.